Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants

Does intratracheal administration of budesonide mixed with surfactant, compared with surfactant alone, reduce bronchopulmonary dysplasia or death by 36 weeks’ postmenstrual age in preterm infants less than 29 weeks’ gestation?In this multicenter randomized trial, after recruiting 641 infants, recruitment was stopped early when prespecified futility criteria were satisfied. There was no difference in bronchopulmonary dysplasia or death between infants receiving budesonide with surfactant (68.5%) vs those receiving surfactant alone (67.9%; adjusted relative risk 1.00 [95% CI, 0.90-1.11]).In extremely preterm infants, mixing budesonide with surfactant did not reduce bronchopulmonary dysplasia or death.

Corresponding Author: Namasivayam Ambalavanan, MD, Women and Infants Center, 176F, Ste 9380, University of Alabama at Birmingham, 1700 Sixth Ave S, Birmingham, AL 35249 (nambalav@uabmc.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.